Elro Pharma Report issue

Foundation Phase 2
Founded: Mulhouse France

Organization Overview

First Clinical Trial
2012
NCT01711398
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1